Free Delivery Over $100
|
|
|||
|
||||
Overview"The present work is aimed at studying the costs of the treatment scheme with the CIMAvax-EGF(R) therapeutic vaccine developed and produced by the Center for Molecular Immunology (CIM) and the comparison with the costs of the oncospecific treatments described in the protocol of action for Non-Small Cell Lung Cancer (NSCLC). The scenario selected for the development of the research is the Surgical Clinical Hospital ""Hermanos Ameijeiras"" (HHA). During the development of the work, the CIM where the vaccine is produced is also characterized and the study of costs is carried out based on the information provided by the HHA. As a result, the costs associated with the treatment of NSCLC by the application of the CIMAvax(R) vaccine are obtained in comparison with the costs of the oncospecific treatments described in the action protocol, with an increase of $217,600.60. Its economic and clinical impact is demonstrated." Full Product DetailsAuthor: Rigoberto Lima-Mart�nez , Olga Torres-Gemeil , Carmen Viada-Gonz�lezPublisher: Our Knowledge Publishing Imprint: Our Knowledge Publishing Dimensions: Width: 15.20cm , Height: 0.50cm , Length: 22.90cm Weight: 0.136kg ISBN: 9786207322787ISBN 10: 6207322789 Pages: 84 Publication Date: 09 April 2024 Audience: General/trade , General Format: Paperback Publisher's Status: Active Availability: In stock  We have confirmation that this item is in stock with the supplier. It will be ordered in for you and dispatched immediately. Table of ContentsReviewsAuthor InformationTab Content 6Author Website:Countries AvailableAll regions |
||||
